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ABSTRACT OF THESIS 
 
 
THE UTILITY OF THE UNIFIED PROTOCOL IN TREATING BORDERLINE 
PERSONALITY DISORDER 
 
Borderline personality disorder (BPD) is characterized by maladaptive levels 
across three personality domains: Neuroticism, (low) Agreeableness, and (low) 
Conscientiousness. The Unified Protocol (UP) is a transdiagnostic treatment that targets 
neuroticism and has demonstrated promising effects with BPD. However, not all 
individuals with BPD respond to UP treatment. The aim of the current study was to explore 
the extent to which the UP is an efficacious treatment for BPD symptoms. This study 
represents a secondary analysis of a clinical trial in which the UP was the study treatment; 
data from the full sample and a subset of nine participants who likely met criteria for BPD 
were included. First, we explored within-group changes in general BPD symptoms, along 
with specific symptom domains. Improvements in total BPD symptoms were not observed 
in the full sample, whereas the UP resulted in moderate overall BPD symptom 
improvement among participants with BPD. Contrary to expectations, emotional 
difficulties did not exhibit larger effects than other domains. We also explored differences 
in within-person change in BPD scores during treatment based on patients’ FFM profiles 
at baseline. Change on BPD symptoms was not predicted by a typical BPD FFM profile. 
Possible explanations for the results and limitations were discussed.  
 







(Name of Student) 
 
12/03/2021 































Shannon Sauer-Zavala, Ph.D. 
Director of Thesis 
 
Mark Fillmore, Ph.D. 
Director of Graduate Studies 
 
12/03/2021 










TABLE OF CONTENTS 
 
LIST OF TABLES ............................................................................................................. iv 
LIST OF FIGURES ............................................................................................................ v 
CHAPTER 1. INTRODUCTION ...................................................................................... 1 
1.1 Background ......................................................................................................... 1 
1.2 Current Study ...................................................................................................... 6 
CHAPTER 2. METHOD ................................................................................................... 8 
2.1 Participants .......................................................................................................... 8 
2.2 Measures ............................................................................................................. 9 
2.2.1 DSM-5 Diagnoses ........................................................................................... 9 
2.2.2 BPD Symptoms ............................................................................................. 10 
2.2.3 FFM Domains ............................................................................................... 11 
2.3 Procedures ......................................................................................................... 11 
2.4 Analytic Approach ............................................................................................ 12 
2.4.1 Characterizing Change in BPD Symptoms During Treatment with the UP . 12 
2.4.2 FFM Dimensions as Predictors of BPD Symptom Improvement ................. 13 
2.5 Power ................................................................................................................ 14 
CHAPTER 3. RESULTS ................................................................................................. 16 
3.1 Characterizing Change in BPD Symptoms During Treatment with the UP ..... 16 
3.2 FFM Dimensions as Moderators of BPD Symptom Improvement .................. 17 
CHAPTER 4. DISCUSSION ........................................................................................... 30 
REFERENCES ................................................................................................................. 36 





LIST OF TABLES 
Table 1: Within Participant Effect Sizes for change in BPD Symptoms in the Full and 
BPD Subset Samples......................................................................................................... 19 
Table 2: Between Condition Effect Sizes for BPD Symptoms as a Function of Treatment 
Length ............................................................................................................................... 21 
Table 3: Baseline FFM Domains as Predictors of BPD Symptom Change in the Full 
Sample............................................................................................................................... 23 




LIST OF FIGURES 
Figure 1: Baseline FFM profile of Patient 1 ..................................................................... 25 
Figure 2: Baseline FFM profile of Patient 2 ..................................................................... 25 
Figure 3: Baseline FFM profile of Patient 3 ..................................................................... 26 
Figure 4: Baseline FFM profile of Patient 4 ..................................................................... 26 
Figure 5: Baseline FFM profile of Patient 5 ..................................................................... 27 
Figure 6: Baseline FFM profile of Patient 6 ..................................................................... 27 
Figure 7: Baseline FFM profile of Patient 7 ..................................................................... 28 
Figure 8: Baseline FFM profile of Patient 8 ..................................................................... 28 




CHAPTER 1. INTRODUCTION 
1.1 Background  
The Unified Protocol (UP; Barlow et al., 2011) is a transdiagnostic 
treatment that targets common mechanisms implicated in the development and 
maintenance of a range of emotional disorders (e.g., anxiety, depressive, and related 
disorders; Barlow, 1991; Cassiello-Robbins et al., 2020). Specifically, the UP targets the 
emotional disorder functional model (Bullis et al., 2019) in which (1) frequently occurring 
negative emotions (neuroticism) are (2) met with aversive reactions that, in turn, lead to 
(3) efforts to avoid or suppress emotional experiences. Aversive/avoidant reactions to 
emotions paradoxically increase the frequency and intensity of negative emotional 
experiences (Aldao & Nolen-Hoeksema, 2010; Cisler & Olatunji, 2012; Ottenbreit et al., 
2014), thereby maintaining the neurotic temperament (e.g., Sauer-Zavala et al., 2020). 
Thus, the UP consists of several core treatment modules broadly aimed at extinguishing 
distress in response to strong emotions (Payne et al., 2014). By targeting aversive reactions 
to a wide variety of negative emotions when they occur, the UP may reduce reliance on 
the avoidant coping that exacerbates negative emotionality. As negative emotions become 
less frequent over time, and when these changes are sustained, these behavioral and 
emotional changes may constitute decreases in neuroticism (Magidson et al., 2014). 
Indeed, the UP is associated with significant decreases in aversive reactions to emotions 
(Eustis et al., 2020; Sauer-Zavala et al., 2012), as well as neuroticism (Carl et al., 2014; 
Sauer-Zavala et al., 2020). This treatment has also demonstrated efficacy in addressing a 
range of emotional disorders, such as generalized and social anxiety disorder, bipolar 
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disorder, obsessive compulsive disorder, and depressive symptoms (Cassiello-Robbins et 
al., 2020; Sakiris & Berle, 2019).  
The UP may also be a useful approach for individuals with borderline 
personality disorder (BPD; see Sauer-Zavala et al., 2016). Specifically, Linehan (1993) 
describes BPD as chiefly characterized by emotional vulnerability (i.e., emotional 
intensity, reactivity, and slow return to baseline functioning) that is akin to the neurotic 
temperament. Indeed, there is ample empirical evidence to suggest that individuals with 
this condition demonstrate high levels of neuroticism relative to other clinical and healthy 
samples (Clarkin et al., 1993; Larstone et al., 2002; Morey, 1991; Samuel & Widiger, 
2008; Saulsman & Page, 2004; Widiger et al., 2013). Additionally, individuals with BPD 
exhibit aversive reactions to negative emotions (the primary target of the UP) that lead to 
the use of emotionally-avoidant coping strategies (Roemer et al., 2005). The actions that 
constitute the behavioral dysregulation included in the diagnostic criteria for BPD (e.g., 
self-injurious behavior, substance use, risky sex, reckless spending) have been shown to 
function as behavioral avoidance from unwanted negative emotions (Aldao & Nolen-
Hoeksema, 2010; Baker et al., 2004; Moore et al., 2008; Tull & Roemer, 2007; Turk et al., 
2005).  
Several small studies have examined the utility of the UP for patients 
diagnosed with BPD. For example, results from one study showed significant reductions 
in BPD symptoms and increases in emotion-regulation capacity for four out of five patients 
with mild to moderate BPD symptoms who completed a course of treatment with the UP 
(Sauer-Zavala et al., 2016). Similarly, in another study, Lopez and colleagues (2015) 
showed that six out of eight participants with BPD who received the UP no longer met 
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diagnostic criteria for this condition at follow up. Some patients in this sample also 
demonstrated improvements in co-occurring symptoms of anxiety and depression (Lopez 
et al., 2019). More recently, Tonarely and colleagues (2020) described a case study using 
the UP to treat an adolescent patient with borderline features. This course of treatment 
resulted in a clinically significant decrease in borderline features, as well as in anxiety and 
depressive symptom severity, from pre-treatment to post-treatment. 
Despite the UP’s promise as a short-term treatment for BPD, some patients 
in these studies did not experience clinically significant improvements in their symptoms. 
For example, symptoms worsened for one of the cases in Sauer-Zavala et al.'s (2016) study. 
The authors noted that this patient was more impulsive and displayed greater 
suspiciousness of others relative to the rest of their sample. The authors then speculated 
that the UP may not be as adept in addressing these specific symptoms of BPD. Similarly, 
in Lopez and colleagues' (2015) sample, two of the eight participants continued to meet 
diagnostic criteria for BPD despite demonstrating remission for comorbid panic disorder 
and specific phobia diagnoses. This pattern of results suggests that UP’s emotion-focus 
may be sufficient for some presentations of BPD (i.e., those with symptoms mediated by 
high levels of neuroticism) but may be incomplete for others. 
Differing treatment responses amongst patients with BPD may be due to 
the high heterogeneity of this condition. To meet the BPD diagnosis, an individual must 
endorse five out of nine diagnostic criteria (American Psychiatric Association [APA], 
2013). As such, there are two hundred fifty-six possible combinations of criteria that might 
render the same diagnosis and two individuals with the same diagnosis of BPD might share 
only one diagnostic criterion (APA, 2013; Smits et al., 2017). Additionally, several studies 
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identified specific subtypes of BPD based on DSM criteria (e.g., Hallquist & Pilkonis, 
2012; Smits et al., 2017). This heterogeneity may be due to the fact that several 
psychopathological mechanisms, beyond neuroticism/emotional dysfunction, have been 
proposed to account for the development of BPD (e.g., insecure attachment, impulsivity); 
if treatments are not engaging the maintaining factors relevant for an individual patient 
with BPD, they may be less likely to respond. In addition to emotional vulnerability 
described by Linehan (1993), two other constructs thought to be implicated in the etiology 
of BPD are discussed below. 
Some theorists contend that insecure attachment processes play a key role 
in the development and maintenance of BPD (Agrawal et al., 2004; Choi-Kain et al., 2009; 
Fonagy et al., 2000, 2003; Sack et al., 1996). The theory of insecure attachment in BPD 
stipulates that the absence of secure caregiver bonds in childhood lies at the core of BPD 
and has lifetime consequences such that adult individuals with BPD do not have the 
confidence in the availability of attachment figures (e.g., friends, romantic partners), 
especially when support, protection, and comfort is sought and needed (Fonagy et al., 
2003; Levy, 2005). As a result, individuals with BPD exhibit an intense need for closeness 
and dependency as well as intense fears of rejection or abandonment. And even though 
these individuals find close relationships important, they are acutely sensitive to subtle 
events in their social environment that frequently lead to volatile relationships, isolative 
behaviors, emotion intensity, and impulsivity (Scott & Pilkonis, 2018). 
Additionally, several studies have implicated trait impulsivity, or the 
tendency to act without careful thought, reflection, or regard for the negative and long-
term consequences (Vandenbos, 2007), as an important risk mechanism for the 
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development and maintenance of BPD (Bornovalova et al., 2005; Crowell et al., 2009; 
Lieb et al., 2004; Links et al., 1999; Terzi et al., 2017; Turner et al., 2017). Like the 
neurotic temperament, the tendency to behave impulsively is biologically-based (Coccaro 
et al., 1993), and may be exacerbated during heightened emotional states (Linehan, 1993; 
Stanley & Singh, 2018). In other words, when faced with intense and uncontrollable 
negative affect, individuals with BPD who are high in impulsivity may engage in extreme 
maladaptive behaviors, such as binge-eating, substance use, gambling, and unsafe sexual 
activities (Jacob et al., 2013; Lieb et al., 2004), along with nonsuicidal self-injurious 
behaviors and suicide attempts (Linehan, 1993; Siever, 2018). In this way, impulsive 
behaviors serve as means to regulate extreme negative emotions which, in turn, perpetuate 
the rise of negative emotions (Stanley & Singh, 2018). Thus, for some individuals with 
high levels of trait impulsivity, addressing negative affect alone (i.e., without targeting 
impulsive behaviors implicated in negative emotion regulation) may not significantly 
reduce BPD behavioral dysfunction. 
It is important to note that these proposed mechanisms for BPD (i.e., 
emotion dysfunction, attachment insecurity, impulsivity) may not be mutually exclusive. 
The Five Factor Model (FFM; Costa & McCrae, 1995) of personality may provide a way 
to characterize an individual’s personality-based risk. The FFM divides personality into 
five dimensional traits, including extraversion, or the tendency to be outgoing and sociable 
(vs. introversion), neuroticism, the frequent and intense experience of negative emotions 
(vs. emotional stability), openness to experience, or the willingness to try new activities 
(vs. closeness to experience), agreeableness, or the quality of being friendly and 
cooperative (vs. antagonism), and conscientiousness, or the ability to evaluate 
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consequences of one’s behavior (vs. impulsivity). Personality disorders are thought to 
emerge as a result of extreme degrees of these traits (Widiger et al., 2009, 2013). Factor 
analytic studies (e.g., Mullins-Sweatt et al., 2012) suggest that BPD may be reflected as 
high levels of neuroticism and low levels of agreeableness (corresponding to the 
attachment-based perspective of BPD) and conscientiousness (corresponding to trait 
impulsivity observed in BPD). This personality structure of BPD is consistent with other 
dimensional models of psychopathology. For example, in the alternative model of 
personality disorders in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition 
(DSM-5; APA, 2013), BPD is characterized by facets of negative affectivity, disinhibition 
(i.e., impulsivity), and psychoticism (i.e., aggression and aloofness). Similarly, in the 
Hierarchical Taxonomy of Psychopathology (HiTOP; Kotov et al., 2017), BPD is 
considered to be located on both the internalizing and antagonistic externalizing 
spectrums.  
These dimensional systems can produce a dimensional profile that can be 
used to develop a personalized treatment plan based on the mechanisms maintaining an 
individual patient’s BPD symptoms. For instance, a patient with elevations largely 
confined to neuroticism subscales will likely benefit from the UP, whereas a patient who 
also exhibits low agreeableness and conscientiousness (not explicitly targeted by the UP) 
may need additional treatment components. 
1.2 Current Study 
The main aim of the current study was to gather preliminary evidence to 
investigate the extent to which the UP is a helpful treatment for BPD using secondary data 
drawn from a sequential multiple assignment randomized trial (SMART; Sauer-Zavala et 
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al., under review). Given previous pilot work exploring the UP’s effect on BPD symptoms 
(reviewed above), we hypothesized that this intervention would result in significant BPD 
symptom improvement among participants who likely met criteria for this condition. 
Additionally, we sought to examine whether specific BPD domains would improve across 
a course of care with the UP among participants who likely met criteria for BPD. Given 
the UP’s focus on emotion dysfunction, we hypothesized that we would observe a larger 
effect for reductions in emotional difficulties relative to identity problems, relationship 
problems, and impulsivity. Lastly, we explored whether there were differences in within-
person change in BPD scores during treatment based on patients’ FFM profiles at baseline. 
We hypothesized that the largest improvements following treatment with the UP would be 
exhibited by individuals with FFM profiles characterized by high neuroticism and at least 
moderate levels of agreeableness and conscientiousness. In contrast, we anticipated that 
those with low levels of agreeableness and/or conscientiousness would demonstrate 
minimal improvements following treatment with the UP.
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CHAPTER 2. METHOD 
2.1 Participants 
Participants included in this study were drawn from a sequential multiple 
assignment randomized trial (SMART), which was designed to determine the feasibility 
and efficacy of sequencing the UP modules based on individual’s strengths or weaknesses 
and whether terminating the treatment prior to delivering the full package would show 
comparable results to the full treatment. The SMART’s treatment-seeking participants 
were recruited from the community via online advertisements and their inclusion criteria 
consisted of being at least 18 years of age and having at least one of the following DSM-
5 (APA, 2013) diagnoses: panic disorder (PD), generalized anxiety disorder (GAD), social 
anxiety disorder (SAD), obsessive-compulsive disorder (OCD), posttraumatic stress 
disorder (PTSD), major depressive disorder (MDD), or persistent depressive disorder 
(PDD). Participants were excluded if they experienced mania within the past year, 
presented with acute suicide risk, met criteria for a substance use disorder within the past 
three months, or had ever experienced delusions or hallucinations. Additionally, 
participants who attended at least five sessions of cognitive behavioral therapy (CBT) in 
the last five years were excluded. Participants were asked to discontinue any other 
psychiatric treatment they might have been receiving before the start of the study and agree 
to maintain a steady dose of their medication throughout the study participation (i.e., from 
the time they consented to the study).  
The parent trial included 57 participants and a subset of participants (n = 9, 
15.8%), who likely met criteria for borderline personality disorder (i.e., individuals with 
pre-treatment Personality Assessment Inventory-Borderline Features Subscale [PAI-BOR; 
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Morey, 1991] total scores ≥ 38 [equivalent to 65T]), and provided data at all timepoints in 
order to a) calculate within-person scores and b) directly compare within-person change 
scores in the same sample between first and second assessments, first and third 
assessments, and second and third assessments. The nine participants’ mean age was 29.22 
(SD = 8.44, range: 20-47), they were mostly female (66.7%) and Caucasian (77.8%). All 
participants finished high school and 66.7% of them had completed an undergraduate 
degree or higher. A little over a half of participants were single and never married (55.6%) 
and approximately two thirds considered themselves straight or heterosexual (66.7%). The 
remaining participants from the parent study (n = 48) were 35.06 old on average (SD = 
12.70, range 19-63), mostly female (66.7%) and Caucasian (77.1%). Everyone in the non-
BPD sample completed high school or GED and 66.6% completed an undergraduate 
degree or higher. 37.5% of the participants were married and one third were single or never 
married (33.3%). Most of this sample (77.1%) considered themselves straight or 
heterosexual. Participant characteristics in both groups were compared via independent 
samples t tests for continuous variables, and c2 tests of independence for nominal and 
categorical variables, but no differences were found.  
2.2 Measures 
2.2.1 DSM-5 Diagnoses 
The Diagnostic Interview for Anxiety, Mood, and Obsessive-Compulsive 
and Related Neuropsychiatric Disorders (DIAMOND; Tolin et al., 2018) was used to 
assess DSM-5 diagnoses for inclusion/exclusion criteria at baseline. The DIAMOND is a 
semi-structured interview that assigns categorical DSM-5 diagnoses and dimensional 
severity ratings (CSRs), using a scale between 1 (normal) and 7 (extreme). The 
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DIAMOND has demonstrated very good (κ = .62) to excellent (κ = 1.00) interrater 
reliability and good (κ = .59) to excellent (κ = 1.00) test-retest reliability on both 
presence/absence of the diagnosis and severity rating; convergent validity was verified by 
significant between-group comparisons on applicable self-report measures for nearly all 
diagnoses (Tolin et al., 2018). Trained graduate students, who administered the 
DIAMOND, demonstrated excellent reliability on categorical ratings of primary diagnoses 
(Krippendorff’s αs: .91-1.00; median = 1.00) and CSRs of each disorder (Krippendorff’s 
αs: .83-1.00; median = .92). 
2.2.2 BPD Symptoms 
Borderline personality disorder symptoms were assessed with the 
Borderline Features Subscale from the Personality Assessment Inventory (PAI-BOR; 
Morey, 1991) at baseline and all follow-up timepoints. This 24-item self-report scale 
provides a total symptom score, as well as subscales for emotional problems assessed by 
affect instability subscale (PAI-BOR-AI), relationship problems assessed by the 
interpersonal relationships subscale (PAI-BOR-IR), identity problems assessed by identity 
disturbance subscale (PAI-BOR-ID), and impulsivity assessed by the self-harm subscale 
(PAI-BOR-SH). Both the construct and discriminant validity were established via 
objective life-event data correlations (Slavin-Mulford et al., 2012). Concurrent validity 
was also established, supporting the utility of PAI-BOR in assessing for BPD diagnosis 
(Stein et al., 2007). The internal consistency of PAI-BOR items in the parent study at 
baseline was acceptable (McDonald’s ω = .64). 
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2.2.3 FFM Domains 
The FFM domains were assessed by the NEO Five-Factor Inventory (NEO-
FFI; McCrae & Costa, 2004) at baseline and all follow-up timepoints. The NEO-FFI is a 
60-item self-report measure with subscales for neuroticism, extraversion, agreeableness, 
conscientiousness, and openness. The items are rated on a 5-point Likert scale, ranging 
from strongly disagree to strongly agree. The internal consistencies reported for all 
domains were good, ranging from .75 to .83 (Costa & McCrae, 1992). The internal 
consistency of NEO-FFI items on the neuroticism subscale in the parent study at baseline 
was good (McDonald’s ω = .82). Internal consistency of NEO-FFI items in the parent 
study at baseline on the extraversion subscale was good (McDonald’s ω = .84), on the 
agreeableness subscale was acceptable (McDonald’s ω = .60), on the conscientiousness 
subscale was excellent (McDonald’s ω = .90), on the openness subscale was acceptable 
(McDonald’s ω = .62). 
2.3 Procedures 
Procedures for the parent trial were approved by the University of Kentucky 
Institutional Review Board. The study procedures were explained to participants and 
informed consent was obtained prior to the start of the study. Following a baseline 
assessment conducted by trained assessors at pre-treatment, participants were randomized 
to either receive the standard delivery of the UP, compensation delivery in which the UP 
modules were sequenced based on participants’ weaknesses, or capitalization delivery in 
which the UP modules were sequenced based on participants’ strengths. After the fifth 
treatment session, a second battery of assessments was administered to participants who 
then underwent a second-stage randomization in which they were assigned to receive Brief 
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(6 sessions) or Full (12 sessions) Treatment conditions. At the end of the Full Treatment, 
the last battery of assessments was administered to all participants, regardless of the length 
of the treatment they received, resulting in three major timepoints. All participants were 
paid $25 for their time at the second and third assessment timepoints. All study data were 
collected and managed using Research Electronic Data Capture (REDCap) tools hosted at 
University of Kentucky (Harris et al., 2009, 2019). 
2.4 Analytic Approach 
2.4.1 Characterizing Change in BPD Symptoms During Treatment with the UP 
In the case of missing data1, listwise deletion was utilized to ensure data at 
all timepoints in order to calculate within-person change scores across timepoints. Data 
were collapsed across treatment sequencing conditions due to the lack of significant 
differences in changes in clinical severity across people assigned to the standard, 
compensation, or capitalization deliveries (Sauer-Zavala et al., under review). Descriptive 
statistics and primary analyses were conducted in SPSS Version 27.0 (IBM Corp., 2020). 
To test the hypotheses regarding the effect of UP treatment on the total BPD score and the 
subscales Hedges’s g was calculated in both the full sample and the BPD subset. Hedges’s 
g allows for the examination of the magnitude of change from the baseline assessment to 
the second assessment (after five sessions of treatment), from baseline to the third 
assessment, and from the second assessment to the third assessment2. The Hedges’s g is a 
preferable approach for analyses of treatment studies because it gives an unbiased estimate 
                                                 
1 Multiple imputation approach did not yield differences in the results and thus raw data were used for 
analyses as a more conservative approach.  
2 All participants received treatment between baseline and second assessment (A2). After A2, participants 
were randomized to either discontinue after their 6th session or after their 12th session. Thus, some 




of the population effect size and is appropriate for small sample sizes (Lakens, 2013). 
Additionally, between group effect sizes, using Hedges’s g, were calculated for BPD 
symptoms at all study timepoints, comparing individuals assigned to the Full and Brief 
Treatment conditions. Hedge’s g is interpreted using the same standards as Cohen's d (i.e., 
0.2, 0.5, and 0.8 reflecting small, medium, and large effects, respectively) and change on 
variables of interest are considered statistically significant if the confidence intervals do 
not include zero. 
2.4.2 FFM Dimensions as Predictors of BPD Symptom Improvement  
To explore whether FFM dimensions predict improvements BPD 
symptoms, we conducted a set of hierarchical regression analyses in the full sample. 
Specifically, we regressed BPD symptoms at assessment 2 (i.e., after 5 weeks of treatment) 
on to baseline BPD symptoms and either neuroticism, agreeableness, or conscientiousness; 
three separate regressions were conducted so that each FFM dimension was included in its 
own model. We elected to examine BPD symptoms as assessment 2 in order to increase 
our power to detect an effect given that all participants received treatment from baseline 
to assessment 2. 
Given that BPD symptoms were relatively low in the full sample (perhaps 
creating a floor effect for improvements), along with the fact that there were only 9 
individuals in our BPD subset, we conducted exploratory analyses to investigate whether 
FFM profiles were related to within-individual change on BPD symptoms. First, we 
examined within participant change on BPD symptoms from pre-treatment to assessment 
2 and from pre-treatment to assessment 3. Significance of within participant change was 
evaluated by calculating a 95% confidence interval (CI) around observed change scores to 
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determine reliability of changes (see: Au et al., 2017); Jacobson and Truax's (1991) method 
was used for calculating standard error of the difference (Sdiff). The Sdiff was calculated 
as a square root of 2*(SE)2 in which the standard error (SE) was computed as SD*sqrt (1 
– rxx). Standard deviation (SD = 13.85) and a reliability coefficient (rxx = 0.91) were taken 
from normative data using the clinical sample in the PAI Professional Manual 2nd Edition 
(Morey, 1991). Sdiff was then multiplied by 1.96 to create a 95% confidence interval (CI) 
around each change score. When this 95% CI does not include zero, change is considered 
statistically significant. Next, to examine whether FFM profiles affect the extent to which 
individual participants respond to the UP, we graphically represented each patient’s FFM 
scores at baseline. Participants were categorized into two groups: 1) high neuroticism 
(average agreeableness and conscientiousness), and 2) low agreeableness and/or low 
conscientiousness. High (T > 55) and low (T < 45) levels on these domains were 
determined by computing t-scores for each participant’s raw score, using normative data 
from the NEO-FFI-3 professional manual (Costa & McCrae, 1992). Finally, we examined 
the proportion of participants in each personality profile group who demonstrated reliable 
change on our measure of BPD symptoms. 
2.5 Power 
Given that this study is a secondary data analysis, a sensitivity analysis to 
determine the strength of the effect that can be reliably detected was conducted (Faul et 
al., 2007). Specifically, we conducted a sensitivity analysis regarding the hypotheses 
regarding the effect of UP treatment on the total BPD score and the subscales. Based on a 
sensitivity power analysis in G*Power Version 3.1 (Faul et al., 2009) assuming α = .05 
(two-tailed), power = 0.80, total sample size = 9, the minimum effect size that could 
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reliably yield a statistically significant result given this study’s sample size was d = 1.07. 
Given the descriptive and exploratory nature of the third aim, investigating whether there 
are differences in within-person change in BPD scores during treatment based on different 




CHAPTER 3. RESULTS 
3.1 Characterizing Change in BPD Symptoms During Treatment with the UP 
Means and standard deviations for the PAI-BOR and each of its subscales 
can be viewed in Table 1 for both the full sample and the BPD sample. Change was in the 
expected direction from baseline to Assessment 2 (i.e., following 5 sessions of UP 
treatment) in all but one instance (i.e., the full sample demonstrated a slight increase on 
the Emotional Problems subscale). In general, any improvements were largely maintained 
at Assessment 3 (i.e., after 12 sessions for individuals in the Full Treatment condition, after 
a 6-week follow-up period for individuals in the Brief Treatment condition). Hedges’s g 
was used to evaluate the magnitude of change on each variable; detailed information 
concerning within-participants effect sizes between assessments are reported in Table 1. 
In the full sample, the degree of change was minimal across all assessment points. 
However, in the BPD subsample, the UP was associated with moderate reductions in total 
BPD symptoms between assessments 1 and 2 and between assessments 1 and 3, along with 
small reductions in the PAI-BOR subscales at these timepoints. Of note, the confidence 
intervals for these effect size estimates included zero, suggesting that these within-group 
improvements were not statistically significant (likely due to our small sample size). 
Additionally, Hedges’s g was also calculated to determine the degree of 
difference on BPD symptoms between the Full and Brief Treatment conditions at all time 
points. The results are reported in Table 2. In line with expectations, there were no 
significant differences between conditions at baseline (when no treatment had been 
administered to either condition) or at assessment 2 (when patients in both conditions had 
received 5 UP sessions), with two exceptions. Patients with BPD in the Full Treatment 
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condition reported significantly lower symptoms of emotional problems than those in the 
Brief Treatment condition at assessment 1; however, by assessment 2, these differences 
were no longer significant. Similarly, patients with BPD in the Full Treatment condition 
reported significantly lower symptoms of identity problems at assessment 2 relative to 
patients in the Brief Treatment condition. With regard to our comparison of substantive 
interest, comparing BPD symptoms at assessment 3 for patients who completed a full 12 
session and patients who completed 6 sessions and a 6-week follow-up period, there were 
no significant differences between groups. In the full sample, differences between 
individuals in the Full Treatment condition and Brief treatment condition on overall BPD 
symptoms, emotional problems, and relationship problems were small in magnitude, 
favoring patients who received all 12 sessions. A similar pattern of results was 
demonstrated for the BPD subset, yet differences between treatment length conditions 
were moderate in magnitude for overall BPD symptoms, emotional problems, and 
relationship problems, along with large differences for identity problems. Again, 
confidence intervals for these effects included zero, indicating that they are not statistically 
significant (again, likely due to small sample size).  
3.2 FFM Dimensions as Moderators of BPD Symptom Improvement 
Separate hierarchical multiple regression models were used to assess 
whether FFM dimensions predict total BPD score at assessment 2 for the full sample, after 
controlling for baseline total BPD scores (see Table 3). Baseline total BPD scores were 
entered at Step 1 for each model, explaining 63.2% of the variance in total BPD scores at 
assessment 2. In Step 2 of each model, agreeableness and conscientiousness were not 
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significant predictors of the total BPD scores at assessment 2, whereas neuroticism was 
marginally significant.  
For our exploratory analyses investigating whether FFM profiles were 
related to within-individual change on BPD symptoms, we first graphically represented 
each patient’s BPD-relevant FFM scores (neuroticism, agreeableness, conscientiousness) 
at baseline (see Figure 1). Using normative data from the NEO-FFI-3 professional manual, 
all patients in the BPD subsample were categorized as exhibiting high neuroticism scores, 
whereas five patients also endorsed low levels of conscientiousness. Of note, no patients 
in our sample were classified as exhibiting low agreeableness.  
Within-individual change on BPD symptoms for our BPD subsample are 
depicted in Table 4; shaded rows represent individuals classified as exhibiting high 
neuroticism and low conscientiousness, whereas non-shaded rows represent those that 
endorsed high neuroticism, only. Across all 9 individuals, only three patients reported 
statistically significant change scores between assessments; however, one of these 
participants’ total BPD score increased from baseline to second assessment, and from 
second assessment to third (see participant 5). Participant 3, who was in Full Treatment 
condition, reported fourteen-points reduction in their overall BPD scores from baseline to 
assessment 2 (statistically significant), but reported 3 points increase at assessment 3, 
rendering their improvement no longer significant. Participant 9, from Brief Treatment 
condition, reported significant decrease in their total BPD scores at assessment 3. Overall, 
there were no discernable patterns in rates of improvement as a function of baseline FFM 
scores.
 
Table 1: Within Participant Effect Sizes for change in BPD Symptoms in the Full and BPD Subset Samples 
Full Sample (N = 59) 
 BL A2 BL to A2 A3 BL to A3 A2 to A3 
 M SD M SD Hedges' g 95% CI M SD 
Hedges' 
g 95% CI 
Hedges' 
g 95% CI 
BPD Symptoms 29.16  9.66 29.09 10.41 0.01 [-0.16, 
1.80] 




Subscales             
Emotional 
Problems 
7.75 3.08 8.11 3.58 -0.11 [-0.31, 
0.10] 






8.18 3.62 7.86 3.47 0.09 [-0.09, 
0.27] 






9.09 3.05 9.00 3.88 0.02 [-0.17, 
0.21] 




Impulsivity 4.14 3.23 4.13 3.12 0.01 [-0.16, 
0.17] 








Table 1 (Continued) 
BPD Subset (n = 9) 
 BL A2 BL to A2 A3 BL to A3 A2 to A3 
 M SD M SD Hedges' g 95% CI M SD 
Hedges' 
g 95% CI 
Hedges' 
g 95% CI 
BPD Symptoms 45.89 4.23 41.78 7.55 0.61  [-0.24, 
1.45] 




Subscales             
Emotional 
Problems 
12.00 2.40 11.44 3.57 0.16 [-0.41, 
0.73] 






12.67 3.24 11.44 3.50 0.34 [-0.33, 
1.02] 






13.00 2.35 12.00 3.97 0.27 [-0.40, 
0.94] 




Impulsivity 8.22 3.90 6.89 3.86 0.33 [-0.03, 
0.68] 







Table 2: Between Condition Effect Sizes for BPD Symptoms as a Function of Treatment Length 
Full Sample 











































































































































































































































Table 3: Baseline FFM Domains as Predictors of BPD Symptom Change in the Full Sample 
 B SE ß p 
Neuroticism 0.26 0.13 0.18 0.053 
Agreeableness -0.20 0.18 -0.10 0.270 
Conscientiousness 0.08 0.10 0.07 0.428 
Note: Dependent variable is BPD symptoms at A2. In addition to the FFM domain (entered 





Table 4: Within-Individual Change in BPD Symptoms for the BPD Subsample   
 BPD Symptoms 



































































Note. †Patient was in full treatment condition. *Denotes significant change score. Participants with high neuroticism and low 
conscientiousness are displayed in shaded rows. The confidence intervals were computed using data from the clinical sample in 
the PAI Professional Manual 2nd Edition. The high and low values of neuroticism, agreeableness, and low conscientiousness 







































































































































































CHAPTER 4. DISCUSSION 
The purpose of the present study was to explore the utility of the Unified 
Protocol (UP) with treatment of borderline personality disorder (BPD) and whether there 
are factors that may affect BPD symptom improvements during treatment. Patients with 
principal anxiety (social anxiety disorder, generalized anxiety disorder, panic disorder), 
depressive (major depressive disorder, persistent depressive), or related (obsessive-
compulsive disorder, posttraumatic stress disorder) disorders received 6 or 12 sessions of 
the UP. A subset of our sample (9 individuals) likely met criteria for comorbid BPD. Given 
that previous research has demonstrated significant improvements in BPD symptoms 
during treatment with the UP (e.g., Lopez et al., 2015; Sauer-Zavala et al., 2016), we 
anticipated similar effects in this study as well. Contrary to expectations, improvements in 
total BPD symptoms were not observed in the full sample, likely due to floor effects 
(scores on the PAI-BOR were quite low in our sample, overall). However, among 
participants who likely met criteria for this condition, our first hypothesis was partially 
supported such that the UP resulted in moderate overall BPD symptom improvement, 
though these changes were not statistically significant.   
One possible explanation for the disparity between the present study’s 
findings and previous research on applying the UP in BPD samples is that prior work (e.g., 
Lopez at al., 2015; Sauer-Zavala et al., 2016) specifically recruited participants with BPD 
diagnoses. Given that these studies were explicitly designed to test the effect of the UP for 
BPD, it is likely that therapists were more compelled to specifically apply UP skills to 
BPD symptoms. Indeed, in Lopez et al. (2015) study, “the UP specifically targeted 
borderline symptomatology.” On the other hand, the present study recruited participants 
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based on anxiety or depressive disorders; BPD symptoms were not assessed on clinician-
rated instruments, so study therapists were likely unaware that some of their patients had 
comorbid BPD. In other words, despite BPD symptoms being functionally related to the 
targets of the UP, therapists might not have asked about/targeted them in treatment. 
Perhaps, for the UP to replicate efficacy with BPD from the abovementioned studies, the 
clinicians need to make a point to use UP skills specifically for BPD symptoms.   
Additionally, the length of the treatment in this study was shorter compared 
to other brief interventions. It is possible that the treatment length was simply not sufficient 
for reductions in BPD symptoms. In the current study, participants underwent 6 (Brief) or 
12 (Full) weeks of treatment. The treatment in the extant studies, mentioned in the 
introduction, focusing specifically on the efficacy of the UP with BPD, lasted between 14 
and 29 weekly session (Lopez et al., 2015; Sauer-Zavala et al., 2016; Tonarely et al., 2020). 
Furthermore, a recent meta-analysis reviewing randomized controlled trials (RCTs) of 
brief BPD interventions (Spong et al., 2021) revealed that although brief interventions may 
be effective, no direct conclusions can be made about the long-term impact of those 
interventions. Notably, all RCTs reviewed in this meta-analysis were between three and 
six months long, suggesting that short-term BPD treatments might be useful, but there is a 
minimum timeframe required for the length of treatment. There was one study of patients 
with BPD in which significant reductions in depression, impulsivity, self-esteem, emotion 
regulation, self-harm, and suicidality were noted only after 12 weeks of group and 
individual therapy that integrated components of dialectical behavior therapy, 
mentalization-based therapy, and other structured treatments (Laporte et al., 2018). 
However, their outcomes did not include BPD symptom severity. Lastly, there is dearth in 
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the literature about BPD treatments as short as 12 sessions and as such, we cannot conclude 
whether 12 weekly sessions were enough to produce significant results in reductions of 
BPD symptoms. 
Given that the UP purports to target negative emotionality, we anticipated 
larger reductions in the emotional problems subscale of the PAI-BOR relative to the other 
subscales. Our second hypothesis was not supported such that, although minimal, a larger 
degree of change was observed for identity problems, relationship problems, and 
impulsivity relative to emotional difficulties between baseline and assessments 2 and 3. It 
is possible that emotional problems measured by the subscale of affective instability, such 
as sudden mood changes (which can be negative), might not be well represented by 
neuroticism targeted by the UP. Also, given that there were no statistically significant 
improvements in BPD symptoms in this sample overall or in the BPD subsample, the effect 
of the UP on emotional problems could have been diluted. Lastly, the confidence intervals 
of the computed effect sizes in all subscales were somewhat similar in ranges, and thus we 
cannot draw sound conclusions about which subscale improved the most.  
Next, we sought to explore whether FFM traits at baseline were associated 
with treatment response to the UP. Extant personality disorder research suggests that BPD 
can be understood as elevations in neuroticism, along with low levels of agreeableness and 
conscientiousness (e.g., Mullins-Sweatt et al., 2012). Given that the UP was developed to 
address neuroticism, we hypothesized that individuals endorsing low levels of 
agreeableness and/or conscientiousness would not respond as well to this intervention. 
Using the full sample to increase our power, regression analyses suggested that change on 
BPD symptoms from baseline to assessment 2 (i.e., following five sessions of the UP) was 
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not predicted by baseline levels of agreeableness, or conscientiousness – contrary to 
expectations. Neuroticism demonstrated a trend towards significance (p = .053), 
suggesting that higher baseline levels of this trait are associated with less improvement in 
BPD symptoms. This finding appears to be consistent with a body of research documenting 
that higher levels of neuroticism predict poorer outcomes in depressive disorders (e.g., 
Bock et al., 2010; Hayden & Klein, 2001; Quilty et al., 2008). It is possible then that the 
already high levels of neuroticism in the current sample precluded improvements in BPD 
symptoms. 
Given that the full sample did not endorse a high degree of BPD symptoms, 
we sought to explore whether baseline personality profiles of patients in our BPD subset 
could be used to predict treatment response. For patients classified as exhibiting high 
neuroticism (and at least moderate levels of agreeableness and conscientiousness), three 
out of four participants (75%) demonstrated reductions in BPD symptoms from baseline 
to assessment 2, and these improvements continued to grow by assessment 3 (of note, only 
one of these participants was in the Full Treatment condition). Although all five 
participants with high neuroticism and low conscientiousness experienced reductions of 
BPD symptoms from baseline to assessment 2, only one of these participants (20%) 
continued experiencing reduction in BPD symptoms by assessment 3. In contrast, four out 
of five participants (80%) with high levels of neuroticism and low levels of 
conscientiousness exhibited worsening symptoms from assessment 2 to assessment 3. 
Thus, our hypothesis regarding within-person change in BPD scores based on patients’ 
FFM profiles was partially supported. Individuals with FFM profiles characterized by low 
conscientiousness may exhibit early gains in treatment but are unable to sustain them 
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across a longer period of time, suggesting the need to engage in this trait in a 
comprehensive treatment for BPD. Additionally, as we already mentioned, the duration of 
the treatment (i.e., 6 or 12 sessions) might have simply not sufficed to treat BPD symptoms 
effectively.  
While this study conveys important information about the utility of the UP 
in treatment of BPD, there are several important limitations that need to be addressed. 
Given that this was a secondary analysis project with a relatively small sample size, we 
were underpowered for regression analyses as well as unlikely to detect significant effects 
in magnitudes of change. Additionally, the number of participants who likely met criteria 
for BPD was also small, as the parent study’s inclusion criteria did not include BPD 
diagnosis, and thus our analyses were not powered to detect change. It is also important to 
note that the BPD disorder was not assessed by the Structured Clinical Interview for DSM-
IV Axis II Disorders (SCID-II; First & Gibbon, 2004) which would yield accurate 
diagnosis. Instead, a total score of 38 or higher (equivalent to 65T) on the self-reported 
Personality Assessment Inventory-Borderline Features Subscale (PAI-BOR; Morey, 
1991) was used to identify participants who would likely meet the criteria for BPD 
diagnosis. Although this instrument has been reasonably reliable in identifying individuals 
with BPD, it might have not been as accurate as a structured clinical assessment. Further, 
our findings may not be generalizable to individuals not seeking treatment for anxiety, 
depressive, and related disorders.  
Despite the limitations in this study, this manuscript is an important step in 
defining the utility of the Unified Protocol with patients with BPD. Specifically, when 
comorbid with anxiety, depressive, and related disorders. In sum, individuals with BPD 
35 
 
experienced small to moderate, yet not statistically significant, improvements in their 
symptoms. However, the participants with BPD who mapped onto the typical FFM profile 
of BPD did not sustain these improvements in the long term. As such, the UP may be 
helpful in treating comorbid BPD symptoms in the short term, but to achieve large and 
sustained improvements, clinicians ought to focus on the BPD symptomology as a primary 
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